8-羟基-4-(2-羟基乙酰基)异苯并吡喃-1-酮 | 146-04-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异香豆素及其衍生物
• 中文名称: 8-羟基-4-(2-羟基乙酰基)异苯并吡喃-1-酮
• 中文别名: 卵孢菌醇
• 英文名称: oosponol
• 英文别名: 8-hydroxy-4-(2-hydroxyacetyl)isochromen-1-one
• CAS: 146-04-3
• 化学式: C₁₁H₈O₅
• 分子量: 220.182
• InChiKey: WRIZJEREXIDJCC-UHFFFAOYSA-N

物化性质

• LogP：
  0.789 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  Acetic acid 2-(8-hydroxy-1-oxo-1H-isochromen-4-yl)-2-oxo-ethyl ester 在 phosphate buffer 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以95%的产率得到8-羟基-4-(2-羟基乙酰基)异苯并吡喃-1-酮
  参考文献：
  名称：

  次生真菌代谢物及其生物学活性，VIII。–抗真菌异香豆素Oosponol的部分合成†

  摘要：

  oosponol（4）的部分合成显示出显着的抗生素活性，已通过酶催化反应完成，包括（-）-oospoglycol（1）的区域选择性乙酰化，然后进行氧化步骤和脂肪酶水解。

  DOI：

  10.1002/jlac.199719970130

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Pharmacological compound having pressure reductive activity
  申请人：——

  公开号：US20020001594A1

  公开（公告）日：2002-01-03

  An object of the present invention is to provide pharmacological compound including a component having pressure reductive activity obtained from Mycoleptodonoides aitchisonii fruit body which is safe and cheap, harvested constantly year-round by artificial cultivation, with equal quality, and useful for prevention and/or amelioration of symptom of hypertension caused by angiotensin I converting enzyme or the like, also to provide food or beverage such as functional drinks including the pharmacological compound and having pressure reductive activity as well as excellent palatability. The object will be attained by preparing food and beverage by using a compound including component having pressure reductive activity obtained from Mycoleptodonoides aitchisonii fruit body, preferably artificially cultivated, especially fungi bed cultivated Mycoleptodonoides aitchisonii fruit body. For example, pharmacological compound including hydrothermal extracted extract juice or extract of fruit body as an effective component useful for prevention and/or symptom amelioration of hypertension, or to prepare food or beverage using the pharmacological compound. Especially when preparing beverage, formation of flocks or browning during storage can be repressed by performing purifying treatment such as bentonite treatment or alcohol treatment or the like after hydrothermal extraction.

  本发明的目的是提供一种药理化合物，其中包括从以下植物中获得的具有压力还原活性的成分 Mycoleptodonoides aitchisonii 本发明的目的是提供从 Mycoleptodonoides aitchisonii 果实中获得的药理化合物，其中包括具有降压活性的成分，该化合物安全、廉价，通过人工栽培常年收获，具有同等质量，可用于预防和/或改善由血管紧张素 I 转换酶或类似物引起的高血压症状，还提供包括该药理化合物的食品或饮料，如具有降压活性和良好适口性的功能饮料。 要实现上述目标，可通过使用一种化合物来制备食品和饮料，该化合物包括从以下植物中获得的具有压力还原活性的成分 Mycoleptodonoides aitchisonii 果实体，最好是人工栽培的，特别是真菌床栽培的 Mycoleptodonoides aitchisonii 子实体。例如，药理化合物包括水热萃取提取果汁或果实提取物，作为预防和/或改善高血压症状的有效成分，或使用药理化合物制备食品或饮料。特别是在制备饮料时，通过在水热萃取后进行纯化处理，如膨润土处理或酒精处理等，可以抑制在贮存过程中形成絮状物或褐变。
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20080161324A1

  公开（公告）日：2008-07-03

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
• US4199598A
  申请人：——

  公开号：US4199598A

  公开（公告）日：1980-04-22
• US4179463A
  申请人：——

  公开号：US4179463A

  公开（公告）日：1979-12-18

表征谱图